Literature DB >> 31316776

Biologics' switching: new insights toward establishing practice norms.

Hussein Mahagna1,2, Shomron Ben-Horin1,2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31316776      PMCID： PMC6620867          DOI： 10.1177/2050640619851683

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  7 in total

1.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Authors:  Bruce E Sands; Richard Kozarek; Jack Spainhour; Charles F Barish; Scott Becker; Lawrence Goldberg; Seymour Katz; Ronald Goldblum; Rena Harrigan; Deborah Hilton; Stephen B Hanauer
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

2.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

3.  Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.

Authors:  S Ben-Horin; B Ungar; U Kopylov; A Lahat; M Yavzori; E Fudim; O Picard; Y Peled; R Eliakim; E Del Tedesco; S Paul; X Roblin
Journal:  Aliment Pharmacol Ther       Date:  2018-02-15       Impact factor: 8.171

4.  Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Authors:  Claire Liefferinckx; Bram Verstockt; Ann Gils; Sophie Tops; Wouter Van Moerkercke; Severine Vermeire; Denis Franchimont
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

5.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

6.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

7.  The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

Authors:  M Schiff; C Pritchard; J E Huffstutter; V Rodriguez-Valverde; P Durez; X Zhou; T Li; K Bahrt; S Kelly; M Le Bars; M C Genovese
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103
  7 in total
  1 in total

Review 1.  Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

Authors:  Guanglin Cui; Jon Florholmen; Rasmus Goll
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.